Loading...

DERM JOURNEY MEDICAL CORP Earnings Reports 8-K Filing

JRNY

DRM

JOURNEY MEDICAL CORP

(DERM)

2024 8-K

Show Summary

Summary

Stock Offering Agreement

Product Expansion

Market Expansion

Financial Statements

Management Change

Financial Results

Financial Update

Financial Results

Financial Results

Financial Results

Amendment to Credit Agreement

Departure of Directors or C...

Earnings Reports

Appointment of CFO

Earnings Reports

Credit Agreement for Term L...

Resignation of Director

Earnings Reports

Compliance Notification and...

Compliance and License Agre...

Earnings Reports

Annual Meeting Approval

Loan Agreement Amendment

Earnings Reports

Management Change

Sales Agreement

External Links:

Journey Medical Corp reported preliminary estimated revenues of $14.6 million for Q3 2024, down from $15.3 million in Q3 2023, and a net loss of $2.4 million, while also announcing FDA approval for its new product Emrosi, with expected revenues between $55-$60 million for 2024.

AI Assistant

JOURNEY MEDICAL CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.